Tetraphase pharmaceuticals inc (TTPH)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'15Dec'14Dec'13Dec'12Dec'11
Operating activities
Net loss

-70,085

-72,158

-114,752

-83,189

-66,742

-29,636

-15,087

-21,564

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

633

576

431

193

124

129

353

521

Non-cash interest expense related to notes payable

621

145

-

-

-

-

-

-

Amortization of deferred financing costs and debt discount

-

-

-

94

226

342

175

78

Accretion of final interest payment on term loans

-

-

-

45

115

199

128

-

Fair value adjustment of warrants and investor right obligation

-

-

-

-

-

-263

63

-22

Stock-based compensation expense

6,435

13,129

11,963

11,616

5,230

1,301

612

312

Loss on extinguishment of debt

-1,568

-

-

-

-

-

-

-

Impairment of equipment related to restructuring

335

-

-

-

-

-

-

-

Gain on asset disposal

83

-

-

-

-

-

-

-

Loss from disposal of property and equipment

-

-

-

-2

-2

-

-

-1

Changes in operating assets and liabilities:
Restricted cash

-

-

-

-

-

63

-

-

Accounts receivable

-772

-2,379

2,864

693

1,752

-746

2,267

185

Contract asset

-3,000

3,000

-

-

-

-

-

-

Inventory

847

748

-

-

-

-

-

-

Prepaid expenses and other assets

-569

-3,708

-200

1,514

1,199

154

227

167

Accounts payable

-781

-2,096

2,751

-1,249

2,224

310

772

-305

Accrued expenses and other liabilities

-5,851

-909

4,816

-2,663

3,983

-

-

-

Accrued expenses and accrued final interest payment on term loan

-

-

-

-

-

3,190

-1,878

1,455

Deferred revenue

-6

-654

-595

651

166

-607

699

-

Operating lease right-of-use assets

1,402

-

-

-

-

-

-

-

Operating lease liabilities

-1,352

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-76,707

-57,623

-24,506

-16,657

-

Net cash used in operating activities

-63,670

-59,628

-98,050

-

-

-

-

-19,876

Investing activities
Acquisition of intangible assets

-

4,750

-

-

-

-

-

-

Proceeds from sale of property and equipment

586

-

-

-

-

-

-

-

Purchases of property and equipment

108

204

771

838

191

129

54

65

Net cash used in investing activities

-

-

-

-838

-191

-129

-54

-

Proceeds from sale of common stock, net of underwriter discounts and issuance costs

-

-

-

162,151

80,766

119,404

-611

-

Net cash provided by (used in) investing activities

478

-4,954

-771

-

-

-

-

-65

Financing activities
Deferred financing fees

-

-

-

-

-

-

85

170

Proceeds from issuance of term loan payable

-

-

-

-

-

3,000

6,200

8,000

Repayment of debt, including final payment

30,480

-

-

4,646

6,126

4,232

2,197

52

Proceeds from sale of common stock and prefunded warrants under a concurrent private placement and registered direct offering, net of issuance costs

7,066

-

-

-

-

-

-

-

Proceeds from issuance of common stock under "at-the-market" equity offering sales agreement, net of issuance costs

-

7,039

92,536

-

-

96

29

-

Proceeds from exercise of warrant

4

-

-

-

-

-

-

-

Proceeds from issuance of debt, net of issuance costs

-

28,949

-

-

-

-

-

-

Proceeds from issuance of stock under stock plans

65

459

610

4,910

1,504

-

-

-

Net cash provided by financing activities

-23,345

36,447

93,146

-

-

-

-

7,810

Net increase (decrease) in cash, cash equivalents and restricted cash

-86,537

-28,135

-5,675

-

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

-

-

32

Net cash provided by financing activities

-

-

-

162,415

76,144

118,268

3,336

-

Net increase (decrease) in cash and cash equivalents

-

-

-

84,870

18,330

93,633

-13,375

-12,131

Supplemental cash flow disclosures from investing activities
Cash paid for interest

1,955

480

-

-

-

-

-

-

Cash paid for interest

-

-

-

363

945

1,142

702

78

Fair value of warrants issued in connection with issuance of term loan

-

-

-

-

-

115

241

302

Reclassification of investors rights/liability to stockholders' equity

-

-

-

-

-

-

-

0

Conversion of convertible preferred stock into common stock

-

-

-

-

-

79,841

-

0

Reclassification of warrant liability to additional paid-in-capital

-

-

-

-

-

462

-

0

Reclassification of deferred financing costs to additional paid-in-capital

-

-

-

-

-

1,261

-

0